Counterpoint Biomedica

Counterpoint Biomedica is a biotechnology company dedicated to addressing the global crisis of antimicrobial resistance (AMR). The company utilizes a proprietary discovery platform to identify small molecule potentiators that restore the efficacy of existing antibiotics against multi-drug resistant (MDR) pathogens. By targeting the underlying mechanisms that bacteria use to evade treatment, Counterpoint aims to revitalize the current pharmacopeia and provide new solutions for life-threatening Gram-negative infections. Their approach focuses on high-unmet-need areas where traditional antibiotic development has stalled, specifically targeting carbapenem-resistant strains. The company was founded on research from NYU Langone Health and is positioned to bridge the gap in the antibiotic development pipeline.